Research & Literature

Staging and response assessment in lymphomas: the new Lugano classification.

Cheson BD

Chinese clinical oncology 2015; (4(1)):5 doi:10.3978/j.issn.2304-3865.2014.11.03.

[Hodgkin's lymphoma and radiotherapy].

Datsenko PV, Panshin GA

Voprosy onkologii 2015; (61(1)):45-51.

Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.

Carlo-Stella C, Santoro A

Biomarkers in medicine 2015; (9(8)):807-17 doi:10.2217/BMM.15.30.

Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma.

Murray P, Bell A

Current topics in microbiology and immunology 2015; (390(Pt 1)):287-313 doi:10.1007/978-3-319-22822-8_12.

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.

van Nimwegen FA, Schaapveld M, Cutter DJ, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(3)):235-43 doi:10.1200/JCO.2015.63.4444.

[Lymphomas].

Lohri A

Praxis 2016; (105(1)):47-52 doi:10.1024/1661-8157/a002237.

Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?

Specht L

Current treatment options in oncology 2016; (17(1)):4 doi:10.1007/s11864-015-0377-x.

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Barrington SF, Kirkwood AA, Franceschetto A, et al.

Blood 2016; (127(12)):1531-8 doi:10.1182/blood-2015-11-679407.

Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Rosenberg AS, Klein AK, Ruthazer R, Evens AM

American journal of hematology 2016; (91(6)):560-5 doi:10.1002/ajh.24346.

NF-κB deregulation in Hodgkin lymphoma.

Weniger MA, Küppers R

Seminars in cancer biology 2016; (39()):32-9.

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Johnson P, Federico M, Kirkwood A, et al.

The New England journal of medicine 2016; (374(25)):2419-29 doi:10.1056/NEJMoa1510093.

Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells.

Pavlovic A, Glavina Durdov M, Capkun V, et al.

Medical science monitor : international medical journal of experimental and clinical research 2016; (22()):2340-6 doi:10.12659/msm.896629.

Hodgkin lymphoma: Pathology and biology.

Mathas S, Hartmann S, Küppers R

Seminars in hematology 2016; (53(3)):139-47.

Treatment of early-stage Hodgkin lymphoma.

Engert A, Raemaekers J

Seminars in hematology 2016; (53(3)):165-70.

Nodular lymphocyte-predominant Hodgkin lymphoma.

Savage KJ, Mottok A, Fanale M

Seminars in hematology 2016; (53(3)):190-202.

Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.

van Leeuwen FE, Ng AK

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):323-330 doi:10.1182/asheducation-2016.1.323.

Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.

Hindié E, Mesguich C, Bouabdallah K, Milpied N

European journal of nuclear medicine and molecular imaging 2017; (44(8)):1254-1257 doi:10.1007/s00259-017-3714-4.

Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.

Dann EJ, Bairey O, Bar-Shalom R, et al.

British journal of haematology 2017; (178(5)):709-718 doi:10.1111/bjh.14734.

Frequency of epstein-barr virus in classical hodgkin Lymphoma.

Azhar M, Din HU, Muhammad I, et al.

Journal of Ayub Medical College, Abbottabad : JAMC 2016; (28(2)):271-275.

Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence.

Ricardi U, Dabaja B, Hodgson DC

Annals of oncology : official journal of the European Society for Medical Oncology 2017; (28(9)):2049-2050 doi:10.1093/annonc/mdx356.

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

Allen PB, Gordon LI

Clinical Medicine Insights. Oncology 2017; (11()):1179554917731072 doi:10.1177/1179554917731072.

Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.

Myers RM, Hill BT, Shaw BE, et al.

Cancer 2018; (124(4)):816-825 doi:10.1002/cncr.31114.

Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.

Ansell SM

American journal of hematology 2018; (93(5)):704-715 doi:10.1002/ajh.25071.

Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden.

Björkholm M, Weibull CE, Eloranta S, et al.

European journal of haematology 2018; (101(1)):106-114 doi:10.1111/ejh.13090.

Long-Term Survival Rates of Patients with Stage III-IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984-2013.

Li Y, Sun H, Yan Y, et al.

The oncologist 2018; (23(11)):1328-1336 doi:10.1634/theoncologist.2017-0541.

Contribution of Epstein⁻Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma.

Vrzalikova K, Sunmonu T, Reynolds G, Murray P

Pathogens (Basel, Switzerland) 2018; (7(3)) doi:10.3390/pathogens7030059.

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.

Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J

OncoTargets and therapy 2018; (11()):4583-4590 doi:10.2147/OTT.S141053.

Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Menter T, Tzankov A

Virchows Archiv : an international journal of pathology 2019; (474(4)):497-509 doi:10.1007/s00428-018-2438-6.

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Kobe C, Goergen H, Baues C, et al.

Blood 2018; (132(21)):2273-2279 doi:10.1182/blood-2018-05-852129.

Update on the role of brentuximab vedotin in classical Hodgkin lymphoma.

Tomassetti S, Herrera AF

Therapeutic advances in hematology 2018; (9(9)):261-272 doi:10.1177/2040620718786833.

Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.

Hutchings M

Cancer journal (Sudbury, Mass.) 2018; (24(5)):215-222 doi:10.1097/PPO.0000000000000336.

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

von Tresckow B, Kreissl S, Goergen H, et al.

The Lancet. Haematology 2018; (5(10)):e462-e473 doi:10.1016/S2352-3026(18)30140-6.

Title not available

Gilardin L, Amorim S, Bernard S, et al.

Bulletin du cancer 2018; (105 Suppl 1()):S50-S58 doi:10.1016/S0007-4551(18)30390-4.

American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.

O'Malley DP, Dogan A, Fedoriw Y, et al.

Annals of diagnostic pathology 2019; (39()):105-110 doi:10.1016/j.anndiagpath.2019.02.001.

Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management.

Sureda A, Domingo-Domenech E, Gautam A

Critical reviews in oncology/hematology 2019; (138()):1-5 doi:10.1016/j.critrevonc.2019.03.016.

CD20+ T Cells in Primary Mediastinal Large B Cell Lymphoma Microenvironment.

Gadgeel M, Al-Qanber B, Buck S, Savaşan S

Cytometry. Part B, Clinical cytometry 2020; (98(1)):16-18 doi:10.1002/cyto.b.21832.

Accelerated atherosclerosis, hyperlipoproteinemia and insulin resistance in long-term survivors of Hodgkin lymphoma during childhood and adolescence.

Cepelova M, Kruseova J, Luks A, et al.

Neoplasma 2019; (66(6)):978-987.

Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

Guru Murthy GS, Szabo A, Hamadani M, et al.

The oncologist 2019; (24(11)):1488-1495 doi:10.1634/theoncologist.2019-0172.

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Fuchs M, Goergen H, Kobe C, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(31)):2835-2845 doi:10.1200/JCO.19.00964.

A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

Makita S, Maruyama D, Maeshima AM, et al.

Asia-Pacific journal of clinical oncology 2020; (16(3)):108-114 doi:10.1111/ajco.13248.

Novel agents and immune invasion in Hodgkin lymphoma.

Merryman RW, LaCasce A

Hematology. American Society of Hematology. Education Program 2019; (2019(1)):243-248 doi:10.1182/hematology.2019000029.

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.

Seshachalam A, Karpurmath SV, Rathnam K, et al.

Journal of global oncology 2019; (5()):1-13 doi:10.1200/JGO.19.00179.

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.

Wagner SM, Melchardt T, Egle A, et al.

European journal of haematology 2020; (104(3)):251-258 doi:10.1111/ejh.13368.

The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.

Bari A, Marcheselli R, Sacchi S, et al.

Annals of hematology 2020; (99(2)):277-282 doi:10.1007/s00277-019-03893-7.

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

Straus DJ, Długosz-Danecka M, Alekseev S, et al.

Blood 2020; (135(10)):735-742 doi:10.1182/blood.2019003127.

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.

Relecom A, Federico M, Connors JM, et al.

International journal of environmental research and public health 2020; (17(5)) doi:10.3390/ijerph17051783.

CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study.

Turunen A, Partanen A, Valtola J, et al.

Transfusion 2020; (60(7)):1519-1528 doi:10.1111/trf.15820.

Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.

Ansell SM

American journal of hematology 2020; (95(8)):978-989 doi:10.1002/ajh.25856.

PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.

Xie W, Medeiros LJ, Li S, et al.

Current hematologic malignancy reports 2020; (15(4)):372-381 doi:10.1007/s11899-020-00589-y.

PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma.

Lang N, Crump M

Therapeutic advances in hematology 2020; (11()):2040620720914490 doi:10.1177/2040620720914490.

Mechanisms of Epstein-Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma.

Wang J, Luo Y, Bi P, et al.

Cancer medicine 2020; (9(15)):5598-5608 doi:10.1002/cam4.3213.

Smoking Behaviors in Survivors of Smoking-Related and Non-Smoking-Related Cancers.

Gritz ER, Talluri R, Fokom Domgue J, et al.

JAMA network open 2020; (3(7)):e209072 doi:10.1001/jamanetworkopen.2020.9072.

Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.

Nikolaenko L, Nademanee A

Future oncology (London, England) 2020; (16(29)):2273-2282 doi:10.2217/fon-2020-0026.

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.

Lin N, Song Y, Zhu J

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2020; (32(3)):303-318 doi:10.21147/j.issn.1000-9604.2020.03.03.

CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.

Menke JR, Spinner MA, Natkunam Y, et al.

Archives of pathology & laboratory medicine 2021; (145(6)):753-758 doi:10.5858/arpa.2020-0135-OA.

The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.

Nagpal P, Descalzi-Montoya DB, Lodhi N

Cancer reports (Hoboken, N.J.) 2021; (4(2)):e1311 doi:10.1002/cnr2.1311.

[Treatment strategy for newly diagnosed classical Hodgkin lymphoma: current achievements using interim PET-guided therapy].

Kusumoto S

[Rinsho ketsueki] The Japanese journal of clinical hematology 2020; (61(9)):1244-1251 doi:10.11406/rinketsu.61.1244.

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.

de Vries S, Schaapveld M, Janus CPM, et al.

Journal of the National Cancer Institute 2021; (113(6)):760-769 doi:10.1093/jnci/djaa194.

Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma.

Al-Hadidi SA, Lee HJ

JCO oncology practice 2021; (17(2)):64-71 doi:10.1200/OP.20.00771.

Genomic Landscape of Hodgkin Lymphoma.

Brune MM, Juskevicius D, Haslbauer J, et al.

Cancers 2021; (13(4)) doi:10.3390/cancers13040682.

Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience.

Abuelgasim KA, Shammari RA, Alshieban S, et al.

Leukemia research reports 2021; (15()):100240 doi:10.1016/j.lrr.2021.100240.

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.

Evens AM, Connors JM, Younes A, et al.

Haematologica 2022; (107(5)):1086-1094 doi:10.3324/haematol.2021.278438.

Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.

Akay OM, Ozbalak M, Pehlivan M, et al.

Hematological oncology 2021; (39(4)):498-505 doi:10.1002/hon.2897.

Significance of trogocytosis and exosome-mediated transport in establishing and maintaining the tumor microenvironment in lymphoid malignancies.

Kawashima M, Higuchi H, Kotani A

Journal of clinical and experimental hematopathology : JCEH 2021; (61(4)):192-201 doi:10.3960/jslrt.21005.

Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews.

Gerardi C, Allocati E, Minoia C, et al.

Cancers 2021; (13(12)) doi:10.3390/cancers13122976.

Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.

Uncu Ulu B, Dal MS, Yönal Hindilerden İ, et al.

Journal of chemotherapy (Florence, Italy) 2022; (34(3)):190-198 doi:10.1080/1120009X.2021.1976912.

9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Gerhard-Hartmann E, Goergen H, Bröckelmann PJ, et al.

British journal of haematology 2022; (196(1)):116-126 doi:10.1111/bjh.17793.

Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.

Wong SM, Ajjamada L, Weiss AC, et al.

Cancer 2022; (128(7)):1365-1372 doi:10.1002/cncr.34065.

Investigating early progression of Hodgkin lymphoma in a two-center analysis.

Yu TC, Yu SC, Wang RC, et al.

Journal of the Formosan Medical Association = Taiwan yi zhi 2022; (121(7)):1215-1222 doi:10.1016/j.jfma.2021.12.025.

CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma.

Veldman J, Rodrigues Plaça J, Chong L, et al.

Oncoimmunology 2022; (11(1)):2033433 doi:10.1080/2162402X.2022.2033433.

Current Status of Stem Cell Transplant in Treatment of Testicular Germ Cell Tumors.

King J, Adra N

Current oncology reports 2022; (24(3)):303-310 doi:10.1007/s11912-022-01204-4.

Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma.

Casagrande N, Borghese C, Aldinucci D

Cancers 2022; (14(10)) doi:10.3390/cancers14102427.

Patients with Classical Hodgkin Lymphoma with Less Than 10.5 CD20-Positive Reed-Sternberg Cells in 10 High-Power Fields Have Better Prognosis.

Lacet DFR, Oliveira CC

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2022; (38(3)):596-600 doi:10.1007/s12288-021-01517-7.

Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.

Lu Z, Teng Y, Ning X, et al.

Cancer 2022; (128(18)):3330-3339 doi:10.1002/cncr.34375.

Patterns of care and outcomes of early stage I-II Hodgkin lymphoma treated with or without radiation therapy.

Weil CR, Parsons MJ, Hutten RJ, et al.

Leukemia & lymphoma 2022; (63(12)):2847-2857 doi:10.1080/10428194.2022.2105325.

Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).

LaCasce AS, Dockter T, Ruppert AS, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(5)):1023-1034 doi:10.1200/JCO.22.00947.

Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.

Martínez C, de Haro ME, Romero S, et al.

Annals of hematology 2023; (102(2)):429-437 doi:10.1007/s00277-022-05011-6.

Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.

Fiaccadori V, Neven A, Fortpied C, et al.

British journal of haematology 2023; (200(6)):731-739 doi:10.1111/bjh.18594.

Quitting smoking after a cancer diagnosis is associated with high-risk neutrophil-to-lymphocyte ratio among tobacco use-related cancer survivors.

Lu Y, Kwong K, Wells J, et al.

Scientific reports 2023; (13(1)):2745 doi:10.1038/s41598-023-27624-1.

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.

Lynch RC, Ujjani CS, Poh C, et al.

Blood 2023; (141(21)):2576-2586 doi:10.1182/blood.2022019254.

[Our experience with the treatment of Hodgkin lymphoma patients].

Illés Á, Garai I, Miltényi Z

Orvosi hetilap 2023; (164(11)):403-410 doi:10.1556/650.2023.32736.

Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.

Winter A, Liu N, Surinach A, et al.

Clinical lymphoma, myeloma & leukemia 2023; (23(7)):527-534 doi:10.1016/j.clml.2023.03.015.

Best practice & research clinical haematology: Screening for breast cancer in hodgkin lymphoma survivors.

Wong SM

Best practice & research. Clinical haematology 2023; (36(4)):101525 doi:10.1016/j.beha.2023.101525.

How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?

Milunović V

Medicina (Kaunas, Lithuania) 2024; (60(2)) doi:10.3390/medicina60020344.

Bone damage and health-related quality of life in Hodgkin lymphoma survivors: closing the gaps.

Mancuso S, Mattana M, Giammancheri F, et al.

Frontiers in oncology 2024; (14()):1201595 doi:10.3389/fonc.2024.1201595.

Characterizing age-related differences in Hodgkin lymphoma in children, adolescents and young adults.

Kendel NE, Stanek JR, Willen FK, Audino AN

Pediatric hematology and oncology 2024; (41(5)):336-345 doi:10.1080/08880018.2024.2337627.

Mind the Pitfall: Solitary Nodular Fasciitis Mimicking Extra-Nodal Manifestation of Hodgkin Lymphoma on [18F]FDG PET/CT.

Markandu S, Blickle A, Burgard C, et al.

Diagnostics (Basel, Switzerland) 2024; (14(8)) doi:10.3390/diagnostics14080783.

Risk of Subsequent Primary Cancers Among Adult-Onset 5-Year Cancer Survivors in South Korea: Retrospective Cohort Study.

Choi YY, Lee M, Kim EH, et al.

JMIR public health and surveillance 2024; (10()):e48380 doi:10.2196/48380.

Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma.

Yadigaroglu K, Scharf S, Gretser S, et al.

Haematologica 2024; (109(10)):3295-3304 doi:10.3324/haematol.2023.284512.

Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305).

Kusumoto S, Munakata W, Machida R, et al.

Cancer science 2024; (115(10)):3384-3393 doi:10.1111/cas.16281.

Histopathologic Features and Differential Diagnosis in Challenging Cases of Nodular Lymphocyte Predominant B-cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Ding Y, Jaffe ES

Journal of clinical and translational pathology 2024; (4(2)):61-69 doi:10.14218/jctp.2024.00015.

Clinicopathologic Insights and Molecular Oncogenesis: Understanding Epstein-Barr Virus-Induced B-cell Lymphoproliferations.

Bronson AS, Zhu Y, Lilley CM, et al.

International journal of surgical pathology 2025; (33(3)):502-515 doi:10.1177/10668969241266933.

Classic Hodgkin lymphoma: An illustrative review of select diagnostic limitations and immunomorphological challenges.

El Hussein S, O'Malley DP

Human pathology 2025; (156()):105678 doi:10.1016/j.humpath.2024.105678.

Has PD-1 blockade changed the standard of care for cHL?

Kuczmarski TM, Lynch RC

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):505-510 doi:10.1182/hematology.2024000574.

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis.

Meng F, Xiang M, Liu Y, Zeng D

BMC cancer 2025; (25(1)):78 doi:10.1186/s12885-024-13400-5.

Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors.

Shanmugam V, Tokcan N, Chafamo D, et al.

bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.01.24.631210.

High PD-L1 Expression in HRS Cells and Macrophages in Tumor Immune Microenvironment Is Associated with Adverse Outcome and EBV Positivity in Classical Hodgkin Lymphoma.

Miljak A, Pavlović A, Benzon B, et al.

International journal of molecular sciences 2025; (26(12)) doi:10.3390/ijms26125592.

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.

Roshal M, Kong IY, Dinalankara W, et al.

bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.08.05.667241.

The clinical value of interim PET/computed tomography scanning in patients with classical Hodgkin's lymphoma and its influence on prognosis in Duhok Province, Kurdistan Region - Northern Iraq.

Qais Faraja T, Mohamedb ZA

Nuclear medicine communications 2026; (47(1)):115-120 doi:10.1097/MNM.0000000000002065.

Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma.

Kristo F, Molinari A, Lan Z, et al.

Future oncology (London, England) 2026; (22(7)):843-852 doi:10.1080/14796694.2025.2609296.